
Cadre Holdings, Inc.: stock overview
Price
$33.42
November 13, 2026Market cap $1.4B
What Ploutos Investor adds for Cadre
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
Cadre had revenue of $733M over the last 12 months and net income of $41M, a net margin of 5.6%. Revenue grew by 8.6% a year on average over the last 5 years. At $33.42 the shares trade at a P/E of 34.7, against a median of 38.0 over the last 4 fiscal years. It has net debt of $306M. It pays a dividend yielding 1.20%.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.
Its SEC filings- Market cap
- $1.4B
- 42.73M shares
- P/E
- 34.7
- Today34.7Median38.0
- Revenue, 12 months
- $733M
- +8.6% a year over 5 years
- Net margin
- 5.6%
- 2025: 7.2%, above 63% of its industry
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
+12.5% a year over 2 years
Fiscal years in figures
CDRE's revenue, profit, cash flow and dividend with each year-end price, from 2020 to 2022, 3 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $1.3B
- $1.4B
- Enterprise value
- $1.7B
- P/E 3-year median: 35.9
- 34.7
- EV / EBIT
- 22.0
- EV / Revenue
- 2.4
- P/B 3-year median: 5.5
- 3.9
- FCF yield 3-year median: 3.3%
- 5.4%
- Earnings yield 3-year median: 2.8%
- 2.9%
Profitability
- Gross margin
- 42.0%
- Operating margin
- 10.8%
- Net margin 3-year median: 7.2%
- 5.6%
- ROIC
- 7.7%
- ROIC, 5-year average
- 10.5%
- ROE
- 12.0%
Growth
- Revenue, yearly change
- +7.5%
- EPS, yearly change
- +13.3%
- FCF, yearly change
- +117.7%
- Revenue, average a year
- +8.6%
- EPS, average a year
- -6.1%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $64M
- Total debt
- $394M
- Of which operating leases
- $25M
- Net debt
- $306M
- Net debt / EBITDA
- 3.1x
- Interest cover
- –
- Current ratio
- 2.35
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield 3-year median: 1.0%
- 1.20%
- Buybacks
- –
- Total returned
- 1.20%
- Shares, yearly change
- +5.2%
Against its industry
Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 38).
Gross margin
42.5%
Above 23% of the 161 companies in its industry, and 59% of all.
Operating margin
11.0%
Above 64% of the 186 companies in its industry, and 66% of all.
Net margin
7.2%
Above 63% of the 189 companies in its industry, and 58% of all.
ROE
13.9%
Above 79% of the 174 companies in its industry, and 73% of all.
ROA
5.7%
Above 69% of the 190 companies in its industry, and 75% of all.
Revenue growth
7.5%
Above 48% of the 186 companies in its industry, and 54% of all.
From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- Cadre Holdings, Inc.
- CIK
- 1860543
- Exchange
- NYSE
- Industry (SIC)
- 3842 · Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 42.73M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with CDRE
- JNJJohnson & Johnson+0,00%Compare with CDRE
- ABBVAbbVie+0,00%Compare with CDRE
- UNHUnitedHealth+0,00%Compare with CDRE
- MRKMerck & Company+0,00%Compare with CDRE
- AMGNAmgen+0,00%Compare with CDRE
- TMOThermo Fisher Scientific+0,00%Compare with CDRE
- ABTAbbott Laboratories+0,00%Compare with CDRE
The full analysis
What do Cadre's filings show?
These are Cadre's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is CDRE's market cap?
Cadre Holdings, Inc.'s market cap is $1.4B, at a price of $33.42 on November 13, 2026 and 42.73M shares.
What is CDRE's P/E?
CDRE's P/E is 34.7, on earnings per share of $0.91 over the last 12 months. The median over the last 4 fiscal years was 38.0.
How much revenue does CDRE have?
Cadre had revenue of $733M over the last 12 months. Over the last 5 years it changed by +8.6% a year on average.
Does CDRE pay a dividend?
Yes. Cadre paid $0.40 per share over the last 12 months, a yield of 1.20% at today's price. All the figures are in the Dividend section.
Where do the figures come from?
From Cadre Holdings, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.